XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The segment revenue, segment profit or loss, and significant segment expenses regularly provided to CODM are summarized as follows (in thousands).
Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
Segment revenue$240 $2,380 $4,486 $61,831 
Less: Segment expenses (1)
Cost of revenue(11)50 — 161 
Research and development
Clinical costs21,017 12,866 61,984 36,791 
Contract manufacturing9,644 10,504 33,043 30,697 
Personnel (2)
27,677 35,885 94,560 125,745 
Licenses, collaborations and contingent consideration76,414 112,532 124,306 123,410 
Other R&D (3)
16,711 23,391 53,724 83,773 
Selling, general and administrative (2)
22,231 25,744 68,458 92,330 
Restructuring, long-lived assets impairment and related charges, net— 12,712 (182)38,939 
Plus: Other segment items (4)
10,302 17,587 36,343 52,644 
Segment and consolidated net loss$(163,141)$(213,717)$(395,064)$(417,371)
(1) Refer to Note 6 Balance Sheet Components for depreciation and amortization expenses included in segment expenses.
(2) Refer to Note 8 Stock-Based Awards for stock-based compensation expenses included in segment expenses.
(3) Other research and development expenses primarily includes non-personnel research expenses, allocated facility and IT expenses, IPR&D impairment, and depreciation expenses.
(4) Other segment items include change in fair value of equity investments, interest income, other expense, net, and (provision for) benefit from income taxes, all of which were presented on the condensed consolidated statements of operations.
Schedule of Revenue from External Customers by Geographic Areas
The following table summarizes segment revenues by geographic area (in thousands). The revenues attributed to the U.S. primarily include the Company's grant revenue. The revenues attributed to foreign regions primarily include collaboration and contract revenues recognized under the Company’s collaboration agreements with GSK, contract revenue generated from clinical supplies provided to foreign companies, and license revenue from the Company’s collaboration with Brii Bio.
Three Months Ended
September 30,		Nine Months Ended
September 30,
Segment revenues attributed to:2025202420252024
U.S.$305 $2,091 $1,726 $9,752 
Foreign
GSK(65)(1,102)(630)49,647 
Other— 1,391 3,390 2,432 
Total segment and consolidated revenue$240 $2,380 $4,486 $61,831